Inivata Adds to Board of Directors with Appointment of Peter Wrighton-Smith

2016, News

Inivata, a global clinical cancer genomics company employing the precision of circulating tumour DNA (ctDNA) analysis to improve personalised healthcare in oncology, has appointed Dr Peter Wrighton-Smith to its Board of Directors.  Dr Wrighton-Smith brings strategic product development and international commercialisation experience to Inivata’s Board along with a broad understanding of the clinical service testing market.

Dr Wrighton-Smith is the Chief Executive Officer and Founder of Oxford Immunotec Global PLC, a high-growth global diagnostics company focussing on monitoring immune-regulated conditions.  Peter has led Oxford Immunotec from the foundation stages, through product development to regulatory approval in over 50 countries, and subsequent worldwide commercialisation via both a kit and a CLIA lab model.  Over that time, Oxford Immunotec has raised five rounds of venture funding prior to an IPO on NASDAQ in 2013.  Dr Wrighton-Smith has a Masters in Engineering, Economics and Management, and a Doctorate in Medical Engineering, both from University of Oxford.

Jeffrey H. Buchalter, Chairman of the Board, Inivata, said: 

“Peter’s strong leadership and commercialisation experience in both the US and UK will further strengthen the Inivata Board as we move towards the launch of InVision.”

 

 

Peter Wrighton-Smith, said: 

“Inivata’s liquid biopsy platform, InVision, has enormous potential.  Their demonstrated best-in-class sensitivity and strategically selected gene panel to target actionable mutations for clinicians promises to revolutionise oncologists’ ability to assess and treat their patients.”

 

 

Inivata’s molecular profiling utilises a robust and reproducible platform exhibiting the highest sensitivity and specificity for the detection of genomic alterations in ctDNA.  eTAm-Seq profiling of clinical samples has revealed the detection of mutations at frequencies that may be missed by less sensitive assays.  The analytical validation of InVision presented at AACR in 2016 supports its use in prospective clinical studies to demonstrate the clinical validation and utility in using ctDNA analysis for precision medicine applications particularly for patients where tumour tissue is limited or unavailable.  Peter Wrighton-Smith’s experience and expertise in international clinical service testing and commercialisation will further advance Inivata’s liquid biopsy initiatives.

 

About Inivata

Inivata is a leader in liquid biopsy. Its InVision® platform unlocks essential genomic information from a simple blood draw to guide and personalize cancer treatment, monitor response and detect relapse. Inivata’s technology is based on pioneering research from the Cancer Research UK Cambridge Institute, University of Cambridge. Its lead product, InVisionFirst®-Lung is commercially available and offers best-in-class sensitivity and turnaround, providing molecular insights that enable clinicians to make more informed treatment decisions for advanced NSCLC patients. Inivata has also launched the personalized RaDaR™ assay – allowing the highly sensitive detection of residual disease and recurrence. Inivata is partnering with pharmaceutical, biotechnology companies and commercial partners in a range of early and late stage cancer development programs. The Company has a CLIA certified, CAP accredited laboratory in Research Triangle Park, NC and R&D laboratories in Cambridge, UK. For more information, please go to www.inivata.com. Follow us on Twitter @Inivata.

 

Media Contacts

Consilium Strategic Communications

Chris Gardner/Angela Gray/Sarah Wilson

Paul Rabin (US)

inivata@consilium-comms.com +44 (0)20 3709 5700, +1 516 503 0271

 

Karen Chandler-Smith

karen.chandler-smith@inivata.com +44 (0)7900 430235

 

Our Technology

Our Solutions

Latest News